Further Observations of the Digital Plethysmography in Response to Auditory Stimuli and Its Clinical Applications
- Underestimation of Treatment Effect in Crossover Trials. Cleophas, Ton J. // Angiology;Sep1990 Part 1, Vol. 41 Issue 9, p673
In crossover trials each subject serves as his own control. For the study of cardiovascular diseases such as hypertension and angina pectoria, properly designed crossover studies are preferred to parallel studies. There is a consider- able between-subject variability of symptoms in some of these...
- Prinzmetal's angina. // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1893
A reference entry for the medical term "Prinzmetal's angina," another word for variant angina, is presented.
- PRELIMINARY INVESTIGATION OF PHENELZINE IN THE MANAGEMENT OF ANGINA PECTORIS. Ende, Milton // Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p81
Twenty patients with angina, pectoris of varying degrees of severity were treated with phenelzine for a period of 3 months. The dosage of phenelzine in all cases was 15 mg three times daily. Six of the 20 patients experienced complete remission of symptoms, in another 11 patients, the frequency...
- STUDIES ON A NEW CORONARY VASODILATOR; l-CHLORO-2,3-PROPANEDIOL DINITRATE. Burgison, Raymond M.; Lu, Gordon G.; Cowley, R. Adams; Krantz Jr., John C. // Angiology;Sep1962, Vol. 13 Issue 9, p412
Focuses on the development of a new coronary vasodilator, 1-chloro-2,3-propanediol dinitrate, for the treatment of angina pectoris. Capacity of the compound to provide a longer duration of vasodilation with less concomitant side-effects; Materials and methods for the development of the new...
- TREATMENT OF ANGINA PECTORIS WITH A NEW CORONARY VASODILATOR, ISOSORBIDE DINITRATE SUBLINGUAL (ISORDIL SUBLORAL). Smith Sr., Arthur L. // Angiology;Sep1962, Vol. 13 Issue 9, p425
Focuses on the use of the coronary vasodilator, isosorbide dinitrate sublingual, for treatment of angina pectoris. Clinical features of angina pectoris; Safety and efficacy of the drug; Recommended dosage for oral isosorbide dinitrate treatment.
- Is it an MI? Yacone, Linda A. // RN;Jun81, Vol. 44 Issue 6, p53
Presents assessment guidelines for diagnosing myocardial ischemia (MI). Causes of angina pectoris resulting from MI; Steps in the nursing assessment of a patient with chest pain; Information on several causes of chest pain. INSETS: WHAT ELSE COULD IT BE?;WHAT TO TELL YOUR ANGINA PATIENTS: A...
- Modified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris: Fact or Fiction. Thadani, Udho // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p331
Discusses the truth behind the modified-release formulation of trimetazidine for exceptional control of angina pectoris. Description of angina pectoris; Cornerstone of therapy to reduce anginal symptoms and increase angina-free exercise capacity; Dosage of antianginal drugs that should be used.
- Treatment of Stable Angina Pectoris with Trimetazidine Modified Release in Indian Primary-Care Practice. Gupta, Rajeev; Sawhney, Jitendra P. S.; Narain, Varun S. // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p325
Introduction: In primary-care practice, trimetazidine is frequently used in combination with other antianginal drugs to enhance antianginal efficacy because of its metabolic mode of action. This study investigates whether a new twice-daily trimetazidine modified release formulation with improved...
- Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Murphy, N. F.; Simpson, C. R.; MacIntyre, K.; Mcalister, F. A.; Chalmers, J.; McMurray, J. J. V. // Heart;Aug2006, Vol. 92 Issue 8, p1047
Objective: To examine the epidemiology, primary care burden and treatment of angina in Scotland. Design: Cross-sectional data from primary care practices participating in the Scottish continuous morbidity recording scheme between 1 April 2001 and 31 March 2002, Setting: 55 primary care practices...